Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated ...

Novavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

The stock's fall snapped a three-day winning streak.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of Novavax (NasdaqGS:NVAX) with a Sell recommendation. Analyst Price Forecast Suggests 141.82% Upside As of June 2, 2025, the ...

Novavax (NVAX) stock dropped after Citi issued a Sell rating, citing concerns over its respiratory vaccine-focused pipeline. Read more here.

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my NVAX stock update.